Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy
The purpose of this study is to find out what effects, good and/or bad, the combination of MK-2206 and AZD6244 hydrogen sulfate or a standard combination of oxaliplatin and fluorouracil (5-FU) called mFOLFOX, has on metastatic pancreatic cancer. MK-2206 and AZD6244 hydrogen sulfate are investigational drugs that have not been approved by the FDA for use in this type of cancer. Participants in this study have pancreatic cancer that has spread and has worsened after one treatment.
Back to Clinical Trials list